Policy experts suggest restricting legal access to the drug for the segment of the population most likely to use the drug will not have the intended effect
The Medical Post 2019 Relatively Ranking shows big variations between top-billing specialties and bottom-billing specialties. Could an element in the U.S. system have an answer?